Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-kB Activation, and Is Active in Patient-Derived Xenograft Models

导出原文传递

翻译打印收藏纠错

作者： Benetatos, Christopher A. ^[1] ; Mitsuuchi, Yasuhiro ^[2] ; Burns, Jennifer M. ; Neiman, Eric M. ; Condon, Stephen M. ; Yu, Guangyao ; Seipel, Martin E. ; Kapoor, Gurpreet S. ; LaPorte, Matthew G. ; Rippin, Susan R. ; Deng, Yijun ; Hendi, Mukta S. ; Tirunahari, Pavan K. ; Lee, Yu-Hua ; Haimowitz, Thomas ; Alexander, Matthew D. ; Graham, Martin A. ; Weng, David ; Shi, Yigong ; McKinlay, Mark A. ; Chunduru, Srinivas K.

作者单位： TetraLog Pharmaceut, Malvern, PA 19355 USA ^[1] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China ^[2]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular cancer therapeutics

2014年13卷4期

867-879页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-kB Activation, and Is Active in Patient-Derived Xenograft Models

Molecular cancer therapeutics

相似文献

Molecular cancer therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-kB Activation, and Is Active in Patient-Derived Xenograft Models

Molecular cancer therapeutics

相似文献

Molecular cancer therapeutics

相关期刊

检索历史清除